Glaucoma Screening With Artificial Intelligence

Sponsor
The University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06012058
Collaborator
Orbis (Other)
3,175
2
18

Study Details

Study Description

Brief Summary

This randomized clinical trial aims to compare the diagnostic performance of two AI-enabled screening strategies - ROTA (RNFL optical texture analysis) assessment versus optic disc photography - in detecting glaucoma within a population-based sample. Secondary objectives are to (1) compare the diagnostic performance of ROTA AI assessment versus OCT RNFL thickness assessment by AI, and ROTA AI assessment versus OCT RNFL thickness assessment by trained graders, (2) investigate the cost-effectiveness of AI ROTA assessment for glaucoma screening, and (3) estimate the prevalence of glaucoma in Hong Kong.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: ROTA assessment by AI
  • Diagnostic Test: Optic disc assessment by AI
N/A

Detailed Description

Glaucoma is the leading cause of irreversible blindness affecting 76 million patients worldwide in 2020. Characterized by progressive degeneration of the optic nerve, early detection of disease deterioration with timely intervention is critical to prevent progressive loss in vision. In the 5th World Glaucoma Association Consensus Meeting, a diverse and representative group of glaucoma clinicians and scientists deliberated on the value and methods of glaucoma screening. Whereas it has been recognized that early detection of glaucoma for treatment is beneficial to preserve the quality of vision and quality of life as glaucoma treatments are often effective, easy to use and well tolerated, the optimal screening strategy for glaucoma has not yet been determined.

ROTA (Retinal Nerve Fiber Layer Optical Texture Analysis) is a patented algorithm designed to detect axonal fiber bundle loss in glaucoma. Unlike conventional Optical Coherence Tomography (OCT) analysis, ROTA uses non-linear transformation to reveal the optical textures and trajectories of axonal fiber bundles, allowing for intuitive and reliable recognition of RNFL abnormalities without the need for normative databases. It can be applied across different OCT models and is particularly effective at detecting focal RNFL defects in early glaucoma and varying degrees of RNFL damage in end-stage glaucoma. The proposed study will address whether the application AI on ROTA is feasible and cost-effective in the setting of glaucoma screening, and whether ROTA would outperform optic disc photography and OCT RNFL thickness assessment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3175 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomized clinical trial with the primary objective to compare the diagnostic performance of two screening strategies - Retinal nerve fiber layer Optical Texture Analysis (ROTA) assessment by Artificial Intelligence (AI) versus (vs.) optic disc photography assessment by AI or trained graders - for detection of glaucoma in a population-based sample.This is a randomized clinical trial with the primary objective to compare the diagnostic performance of two screening strategies - Retinal nerve fiber layer Optical Texture Analysis (ROTA) assessment by Artificial Intelligence (AI) versus (vs.) optic disc photography assessment by AI or trained graders - for detection of glaucoma in a population-based sample.
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Glaucoma Screening With Artificial Intelligence - A Randomized Clinical Trial Comparing Retinal Nerve Fiber Layer Optical Texture Analysis and Optic Disc Photography Assessment
Anticipated Study Start Date :
Aug 26, 2023
Anticipated Primary Completion Date :
Aug 25, 2024
Anticipated Study Completion Date :
Feb 25, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Retinal nerve fiber layer optical texture analysis (ROTA)

The RNFL is imaged with OCT for ROTA.

Diagnostic Test: ROTA assessment by AI
The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.

Active Comparator: Optic disc photography

The optic disc is imaged with color fundus camera.

Diagnostic Test: Optic disc assessment by AI
The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.

Outcome Measures

Primary Outcome Measures

  1. Diagnostic performance for detection of glaucoma [up to ~1 year]

    The area under the receiver operating characteristic curve (AUC) for detection of glaucoma

Secondary Outcome Measures

  1. Incremental cost-effectiveness ratios (ICERs) for population screening of glaucoma [up to ~1 year]

    ICER for glaucoma screening measured by incremental cost per true positive case detected, incremental cost per incremental QALY

  2. The prevalence of glaucoma [up to ~1 year]

    Proportion of patients with glaucoma

Other Outcome Measures

  1. Diagnostic performance for detection of macular diseases [up to ~1 year]

    The area under the receiver operating characteristic curve (AUC) for detection of macular diseases

  2. Incremental cost-effectiveness ratios (ICERs) for population screening of glaucoma and macular diseases [up to ~1 year]

    ICER for glaucoma and macular diseases screening measured by incremental cost per true positive case detected, incremental cost per incremental QALY

  3. The prevalence of macular diseases [up to ~1 year]

    Proportion of patients with macular diseases

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Individuals aged 50 years or above
Exclusion Criteria:
  • Physically incapacitated

  • Not able to cooperate for clinical examination or optical coherence tomography (OCT) investigation will be excluded

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The University of Hong Kong
  • Orbis

Investigators

  • Principal Investigator: Christopher Leung, The University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Professor Christopher K.S. Leung, Clinical Professor, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT06012058
Other Study ID Numbers:
  • H012_Protocol_Glaucoma
First Posted:
Aug 25, 2023
Last Update Posted:
Aug 29, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Professor Christopher K.S. Leung, Clinical Professor, The University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 29, 2023